SCHEMBL5369261

SCHEMBL5369261

COc1ccc2c(n1)CC(=O)N2CCCOCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TEAD3 Q99594 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
RECQL P46063 1/20 0.36
BLM P54132 1/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
PKM P14618 1/20 0.35
APP P05067 1/20 0.35
HTR7 P34969 2/20 0.35
DRD2 P14416 1/20 0.35
DRD5 P21918 1/20 0.35
DRD3 P35462 1/20 0.35
GBA1 P04062 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5372018 0.79 BMPR1B (0.39) MEN1KMT2AL3MBTL1KDM4EUSP2
SCHEMBL5372098 0.77 MEN1 (0.39) MEN1KMT2ATEAD3TDP1L3MBTL1
SCHEMBL1150252 0.70 HPGD (0.46) MEN1KMT2ATDP1L3MBTL1KDM4E
SCHEMBL5372929 0.68 MEN1 (0.42) MEN1KMT2ATEAD3TDP1L3MBTL1
SCHEMBL1401654 0.67 GSK3A (0.56) MEN1KMT2ATEAD3KDM4EUSP2
SCHEMBL17239978 0.67 ALDH1A1 (0.59) MEN1KMT2ATEAD3TDP1L3MBTL1
SCHEMBL6043712 0.66 MAPT (0.64) TDP1L3MBTL1MAPTMAOB
SCHEMBL15850920 0.66 CYP1A2 (0.53) MEN1KMT2AUSP2RECQL
SCHEMBL17240031 0.65 SHMT2 (0.47) MEN1KMT2ATEAD3L3MBTL1MAPT
SCHEMBL281897 0.64 ALDH1A1 (0.68) KMT2AL3MBTL1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235550-B2 Polycyclic azaindole compounds LES LABORATOIRES SERVIER (FR) 2007-06-26 US disclosed
US-6667304-B2 Affinity for melatonin receptors; sleep disorders; N-(2-(2-methoxy-6H-pyrido(2',3':4,5)pyrrolo(2,1-a)isoindol-11 -yl)ethyl)acetamide; N-(2-(3-methoxy-6,7,8,9-tetrahydropyrido (3,2-b)indolizin-5-yl) ethyl)acetamide LES LABORATOIRES SERVIER (FR) 2003-12-23 US disclosed
US-20030134847-A1 New polycyclic azaindole compounds GUILLAUMET GERALD (FR) 2003-07-17 US disclosed
US-20030105087-A1 For therapy of melatoninergic disorders GUILLAUMET GERALD (FR) 2003-06-05 US disclosed
EP-1092717-B1 Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-01-08 EP disclosed
US-6495543-B1 TREATING OR PREVENTING MELATONINERGIC DISORDERS LES LABORATOIRES SERVIER (FR) 2002-12-17 US disclosed
EP-1092717-A2 Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134847-A1 New polycyclic azaindole compounds AZI2, DRD3, CCNI MEN1 357/4885KMT2A 329/4885TEAD3 1627/4885
US-20030105087-A1 For therapy of melatoninergic disorders MTNR1A, MTNR1B, TPH1 MEN1 600/4885KMT2A 865/4885TEAD3 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.